SomnoMed Ltd (ASX:SOM) is facing a more challenging outlook after flagging a FY26 Revenue shortfall and undergoing a Leadership change, even as the sleep-health company continues to grow sales and improve margins. At the close of 12 August 2026, SomnoMed shares were trading at A$0.40, unchanged on the day, after reaching an intraday low of A$0.39.

What happened to SomnoMed shares?

SomnoMed's latest update highlighted a gap between continued operational progress and softer revenue expectations.

In its 27 July trading update, the company said preliminary, unaudited FY26 revenue was expected to be approximately A$114 million to A$115 million, below its previous guidance of A$119 million to A$126 million.

Management attributed the revenue shortfall primarily to weaker conditions in Europe, including changes to reimbursement policies and referral pathways, as well as the impact of currency movements.

The Earnings impact is expected to be more limited, with EBITDA forecast towards the middle of the previously indicated A$10 million to A$12 million range.

What is driving the story?

The central issue for SomnoMed is whether its improving operational performance can offset weaker conditions in some markets.

The company develops customised oral appliances used in the treatment of obstructive sleep apnoea (OSA). Its underlying sales trajectory has remained positive, while margins have improved.

However, European market conditions have created a near-term challenge. Changes to reimbursement arrangements and referral pathways have affected Demand expectations and prompted the FY26 revenue revision.

Latest ASX announcements

SomnoMed's 27 July update also outlined the controlled global rollout of Virtus, a new oral appliance designed for patients with both obstructive sleep apnoea and sleep bruxism, or teeth grinding.

The company estimates that the combination affects a substantial proportion of people with OSA. Virtus is intended to address this overlap, providing SomnoMed with another potential avenue for product expansion.

Management also indicated that it expects high single-digit revenue growth in FY27, with EBITDA margins broadly consistent with FY26.

The company's audited FY26 results and FY27 guidance are scheduled for 28 August 2026, making the upcoming results a significant milestone for the business.

SomnoMed's first-half FY26 results provided evidence of the company's underlying growth, with record first-half revenue of A$60.7 million, up 13%, while EBITDA increased 35% to A$7.8 million.

Financial position

SomnoMed has been working to combine revenue growth with improved earnings performance.

FY25 revenue increased to approximately A$111.5 million, accompanied by a significant improvement in EBITDA and positive cash flow, although the company continued to report a net loss.

For FY26, preliminary revenue of approximately A$114 million to A$115 million and EBITDA around the middle of the A$10 million to A$12 million guidance range would represent continued operational progress despite the revenue downgrade.

The audited FY26 accounts will provide further detail on the company's cash position, profitability and balance sheet.

Bull case

The positive case for SomnoMed centres on continued growth in demand for oral-appliance therapy for sleep apnoea.

The company has continued to increase revenue while improving margins, giving it an opportunity to strengthen earnings as the Business expands.

Product development also provides additional growth opportunities. Virtus is being rolled out globally for patients with OSA and sleep bruxism, while the FDA-cleared Rest Assure device, which incorporates compliance monitoring, is planned for a soft FY27 launch.

If European conditions stabilise and the company's newer products gain commercial traction, SomnoMed could potentially return to a stronger growth trajectory.

Bear case

The main challenge remains Europe.

Changes to reimbursement policies and referral pathways have already contributed to the FY26 revenue downgrade. If these conditions persist, they could make the company's FY27 growth target more difficult to achieve.

Currency movements are another Factor that can affect reported revenue.

SomnoMed also needs to demonstrate that improved EBITDA performance can translate into sustained statutory profitability. The upcoming audited FY26 results will provide greater clarity on the durability of the company's earnings improvement.

What could move the shares next?

The key upcoming event is SomnoMed's audited FY26 results and FY27 guidance on 28 August 2026.

The market will be focused on the final FY26 revenue and EBITDA outcomes, the company's cash position and management's outlook for growth.

Commercial progress with Virtus and Rest Assure could also influence the company's growth profile, while developments in European reimbursement arrangements and referral pathways remain important to the outlook.

Bottom line

SomnoMed Ltd (ASX:SOM) is navigating a combination of encouraging operational progress and near-term challenges.

Revenue continues to grow and margins have improved, but weaker European conditions have forced the company to reduce its FY26 revenue expectations. The leadership transition and upcoming product launches add further moving parts to the story.

At the close of 12 August 2026, SomnoMed shares traded at A$0.40, unchanged on the day, after touching an intraday low of A$0.39.

The company's audited FY26 results and FY27 outlook on 28 August will provide a clearer picture of whether improving earnings, new products and underlying sales growth can offset the challenges facing its European operations.